Accepted Manuscript



Comparative Effectiveness of Enoxaparin versus Dalteparin for Thromboprophylaxis after Traumatic Injury

Todd A. Miano, PharmD, MSCE, Adam Cuker, MD; MS, Jason D. Christie, MD MSCE, Niels Martin, MD, Brian Smith, MD, MPH, Amy T. Makley, MD, Wensheng Guo, PhD, Sean Hennessy, PharmD, PhD

PII: S0012-3692(17)31407-1

DOI: 10.1016/j.chest.2017.08.008

Reference: CHEST 1254

To appear in: *CHEST*

Received Date: 8 June 2017

Revised Date: 10 July 2017

Accepted Date: 1 August 2017

Please cite this article as: Miano TA, Cuker A, Christie JD, Martin N, Smith B, Makley AT, Guo W, Hennessy S, Comparative Effectiveness of Enoxaparin versus Dalteparin for Thromboprophylaxis after Traumatic Injury, *CHEST* (2017), doi: 10.1016/j.chest.2017.08.008.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Comparative Effectiveness of Enoxaparin versus Dalteparin for Thromboprophylaxis after Traumatic Injury

Running head: Enoxaparin vs. Dalteparin in Trauma

Corresponding Author:
Todd A. Miano, PharmD, MSCE[1,2,3]
Email: tmiano81@gmail.com
Address: 423 Guardian Drive
109 Blockley Hall
Philadelphia, PA 19104

Co-Authors:
Adam Cuker, MD; MS[4,5]*; Jason D. Christie, MD MSCE*[2,6]*; Niels Martin, MD*[7]*; Brian Smith, MD, MPH*[7]*; Amy T. Makley, MD*[8]*; Wensheng Guo, PhD*[2,3]*; Sean Hennessy, PharmD, PhD*[1,2,3]

Affiliations
1. Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine at the University of Pennsylvania
2. Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania
3. Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine at the University of Pennsylvania
4. Department of Medicine, Perelman School of Medicine at the University of Pennsylvania
5. Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania
6. Pulmonary, Allergy, and Critical Care Division, Perelman School of Medicine at the University of Pennsylvania
7. Division of Traumatology, Surgical Critical Care and Emergency Surgery, Perelman School of Medicine at the University of Pennsylvania
8. Department of Surgery, University of Cincinnati College of Medicine

Funding: This work was supported by grants from the National Institutes of Health F32HL124914 (TAM) T32GM075766 (TAM and SH), HL115354 (JDC), and HL087115 (JDC).

Disclosures: AC has served as a consultant for Biogen-Idec, Diagnostica Stago, and Genzyme and has received research support from Bayer, Biogen-Idec, Spark Therapeutics, Shire, and T2 Biosystems. SH has served as a consultant for Sanofi and also directs a center that receives educational support from Pfizer. All other authors have no conflicts of interest to disclose.

Portions of the data used in this study have been presented at the American College of Surgeons Clinical Congress, Washington DC, October 2016 and the Society of Critical Care Medicine's annual congress in Honolulu, Hawaii, January 2017

Abstract word count: 248
Manuscript text word count: 2727

Abbreviations

Download English Version:

https://daneshyari.com/en/article/8658097

Download Persian Version:

https://daneshyari.com/article/8658097

Daneshyari.com